Title

Extending the scope of individual patient data meta-analyses: merging algorithms for biomarker measurements from heterogeneous laboratory platforms. The CoLAB Preeclampsia Angiogenic Factor Study.

Authors

*Burke Ó¹, *Benton S², *Szafranski P¹, *von Dadelszen P², Buhimschi C³, Cetin I⁴, Chapell L⁵, Figueras F⁶, Galindo A⁷, Herraiz I⁷, Holzman C⁸, Hubel C⁹, Knudsen U¹⁰, Kronborg C¹⁰, Laivuori H¹¹, McElrath T¹², Moertl M¹³, Myers J¹⁴, Ness RB¹⁵, Oliveira L¹⁶, Olson G¹⁷, Poston L⁵, Ris-Stalpers C¹⁸, Roberts J⁹, Schistermann E¹⁹, Steegers E²⁰, Stepan H²¹, Lapaire O²², Schlembach D¹³, Timmermans S²⁰, Tsatsaris V²³, van der Post JA¹⁸, Verlohren S²⁴, Villa PM¹¹, Williams D²⁵, Zeisler H²⁶, Zhang C¹⁹, *Redman C¹ and *Staff AC²⁷, for the Global Pregnancy CoLaboratory

Corresponding Author: Burke, Ó.

Authors in bold appear in abstract as submitted

Affiliations

* Members of CoLaboratory Angiogenic Factor Protocol Committee

2. University of British Columbia, Vancouver, BC, Canada
3. Yale University, New Haven, CT, USA
4. University of Milan, Italy
5. King's College London, London, UK
6. University of Barcelona, Barcelona, Spain
7. University of Madrid, Spain
8. Michigan State University, East Lansing, MI, USA
9. University of Pittsburgh, Pittsburgh, PA, USA
10. Aarhus University, Aarhus, Denmark
11. University of Helsinki, Helsinki, Finland
12. Harvard Medical School, Boston, MA, USA
13. University of Jena, Germany
14. University of Manchester, Manchester, UK
15. University of Texas, School of Public Health, Houston, TX, USA
16. Federal University of Sao Paulo, Sao Paulo, Brazil
17. University of Texas, Galveston, TX, USA
18. University of Amsterdam, Amsterdam, The Netherlands
Abstract

Objectives: Circulating placental growth factor (PlGF) is a potential biomarker for preeclampsia. Prior studies show its limited precision in predicting or diagnosing preeclampsia, underscoring a common problem in biomarker data analyses in general - that large studies are needed to overcome clinical heterogeneity and to provide sufficient statistical power. Attaining such sample sizes often requires aggregation of cohorts. Different studies may use disparate platforms for laboratory analyses, complicating data merging. Here, we assessed whether PlGF concentrations could be merged across studies using inter-platform standardization.

Methods: Of 16516 pregnancies from 23 cohorts, 12804 had at least one PlGF concentration (gestational age >20 weeks), analysed using one of four platforms: R&D Systems, Alere-Triage, Roche-Elecsys or Abbott-Architect. Two merging algorithms, using Z-Score or Multiple of Median (MOM) transformations, were applied. A single Best Reference Curve (BRC), based on merged non-case PlGF concentrations, was constructed. Case-identification performance of the BRC for PlGF was compared to platform-specific curves.

Results: PlGF concentrations from different analytical platforms were merged (Z-scores marginally better than MOMs) and, overall, BRC case-identification rates out-performed platform-specific curves.

Conclusion: Laboratory measurements from different platforms can be standardised and merged to give reference curves from aggregated PlGF datasets. This method allows for analysis of PlGF as a diagnostic marker for preeclampsia and is generalisable to other medical questions, thereby extending the scope of individual studies to answer a variety of important medical questions.